ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.

TNGX Tango Therapeutics Inc

7.91
0.06 (0.76%)
08 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Tango Therapeutics Inc TNGX NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.06 0.76% 7.91 17:00:10
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
7.70 7.43 7.96 7.91 7.85
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
08/5/202406:21EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/5/202406:14EDGAR2Form 8-K - Current report
08/5/202406:00BWTango Therapeutics Reports First Quarter 2024 Financial..
01/4/202415:48BWTango Therapeutics Announces Inducement Grants Under Nasdaq..
18/3/202406:00BWTango Therapeutics Reports Fourth Quarter and Full Year 2023..
06/3/202406:00BWTango Therapeutics to Participate in Upcoming Investor..
05/3/202415:47GLOBETango Therapeutics to Highlight Preclinical Data on..
08/2/202420:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/2/202420:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/2/202406:00EDGAR2Form 8-K - Current report
05/2/202415:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/2/202415:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/1/202406:00GLOBETango Therapeutics to Present at the Guggenheim Healthcare..
05/1/202415:05GLOBETango Therapeutics Announces Inducement Grants Under Nasdaq..
04/1/202401:47PRNUSMedivir´s licensee, Tango Therapeutics, has dosed the first..
03/1/202406:00GLOBETango Therapeutics Announces First Patient Dosed in Phase..
13/11/202306:00GLOBETango Therapeutics to Highlight Preclinical Data on PRMT5..
08/11/202306:29EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/11/202306:07EDGAR2Form 8-K - Current report
08/11/202306:00GLOBETango Therapeutics Reports Third Quarter 2023 Financial..
07/11/202306:00GLOBETango Therapeutics to Present at the Jefferies London..
02/11/202315:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/10/202316:23EDGAR2Form SC 13D/A - General statement of acquisition of..
18/9/202306:00GLOBETango Therapeutics to Highlight Preclinical Data on..
11/9/202323:15EDGAR2Form EFFECT - Notice of Effectiveness
06/9/202306:00GLOBETango Therapeutics Announces FDA Clearance of..
05/9/202306:00GLOBETango Therapeutics to Participate in the H.C. Wainwright..
01/9/202306:34EDGAR2Form S-3 - Registration statement under Securities Act of..
31/8/202315:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/8/202315:05EDGAR2Form 3 - Initial statement of beneficial ownership of..
30/8/202305:04EDGAR2Form 8-K - Current report
29/8/202316:08GLOBETango Therapeutics Announces Updates to Its Board of..
28/8/202306:00GLOBEMedicenna Announces the Appointment of Jeff Caravella as..
21/8/202315:16EDGAR2Form SC 13G - Statement of acquisition of beneficial..
16/8/202315:40EDGAR2Form SC 13D/A - General statement of acquisition of..
10/8/202306:24EDGAR2Form 8-K - Current report
10/8/202306:00GLOBETango Therapeutics Announces $80 million Private Placement..
07/8/202306:57EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/8/202306:25EDGAR2Form 8-K - Current report
07/8/202306:00GLOBETango Therapeutics Reports Second Quarter 2023 Financial..
24/7/202306:00GLOBETango Therapeutics Announces First Patient Dosed in TNG260..
01/6/202306:00GLOBETango Therapeutics to Participate in Upcoming Investor..

Su Consulta Reciente

Delayed Upgrade Clock